Aratana Therapeutics (PETX) Receives Daily Media Impact Rating of 0.30
News stories about Aratana Therapeutics (NASDAQ:PETX) have been trending positive this week, Accern reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aratana Therapeutics earned a media sentiment score of 0.30 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 47.5400053225112 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:
- Peter Steven St Sells 50,000 Shares of Aratana Therapeutics, Inc. (PETX) Stock (americanbankingnews.com)
- Aratana Therapeutics (PETX) and Eli Lily (LLY) Division Elanco Animal Health Reports Positive Opinion on … – StreetInsider.com (streetinsider.com)
- With three products out, Aratana chases its fourth: a canine cancer drug (finance.yahoo.com)
- FY2017 Earnings Estimate for Aratana Therapeutics, Inc. Issued By William Blair (PETX) (americanbankingnews.com)
- William Blair Comments on Aratana Therapeutics, Inc.’s FY2020 Earnings (PETX) (americanbankingnews.com)
Aratana Therapeutics (NASDAQ:PETX) traded up $0.15 during trading hours on Monday, hitting $7.05. 420,400 shares of the stock were exchanged, compared to its average volume of 402,166. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.08 and a current ratio of 3.42. Aratana Therapeutics has a 12 month low of $4.97 and a 12 month high of $8.63.
Aratana Therapeutics (NASDAQ:PETX) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.24) by $0.03. The company had revenue of $6.16 million for the quarter, compared to analyst estimates of $6.47 million. Aratana Therapeutics had a negative net margin of 358.55% and a negative return on equity of 48.79%. The company’s quarterly revenue was up 1440.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.38) EPS. equities research analysts forecast that Aratana Therapeutics will post -1.04 earnings per share for the current year.
PETX has been the subject of a number of research analyst reports. BidaskClub cut shares of Aratana Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. ValuEngine raised shares of Aratana Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 25th. Jefferies Group LLC set a $8.00 target price on shares of Aratana Therapeutics and gave the stock a “buy” rating in a report on Friday, August 4th. Lake Street Capital reduced their target price on shares of Aratana Therapeutics from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, August 25th. Finally, Zacks Investment Research raised shares of Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $7.75 target price on the stock in a report on Thursday. Two investment analysts have rated the stock with a sell rating and five have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $8.19.
WARNING: “Aratana Therapeutics (PETX) Receives Daily Media Impact Rating of 0.30” was originally posted by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.watchlistnews.com/aratana-therapeutics-petx-receives-daily-media-impact-rating-of-0-30/1701051.html.
In related news, insider Peter Steven St sold 50,000 shares of the stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $6.24, for a total transaction of $312,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, COO Brent Standridge sold 10,000 shares of the company’s stock in a transaction on Monday, September 25th. The stock was sold at an average price of $6.11, for a total transaction of $61,100.00. Following the transaction, the chief operating officer now owns 70,267 shares in the company, valued at approximately $429,331.37. The disclosure for this sale can be found here. Over the last three months, insiders have sold 120,000 shares of company stock worth $785,600. 5.20% of the stock is owned by insiders.
Aratana Therapeutics Company Profile
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.